The Korean Society for Neuro-Oncology (KSNO) Guideline for Glioblastomas: Version 2018.01
- Author:
Young Zoon KIM
1
;
Chae Yong KIM
;
Jaejoon LIM
;
Kyoung Su SUNG
;
Jihae LEE
;
Hyuk Jin OH
;
Seok Gu KANG
;
Shin Hyuk KANG
;
Doo Sik KONG
;
Sung Hwan KIM
;
Se Hyuk KIM
;
Se Hoon KIM
;
Yu Jung KIM
;
Eui Hyun KIM
;
In Ah KIM
;
Ho Sung KIM
;
Tae Hoon ROH
;
Jae Sung PARK
;
Hyun Jin PARK
;
Sang Woo SONG
;
Seung Ho YANG
;
Wan Soo YOON
;
Hong In YOON
;
Soon Tae LEE
;
Sea Won LEE
;
Youn Soo LEE
;
Chan Woo WEE
;
Jong Hee CHANG
;
Tae Young JUNG
;
Hye Lim JUNG
;
Jae Ho CHO
;
Seung Hong CHOI
;
Hyoung Soo CHOI
;
Je Beom HONG
;
Do Hoon LIM
;
Dong Sup CHUNG
;
Author Information
- Publication Type:Original Article
- Keywords: Korean Society for Neuro-Oncology; Guideline; Glioblastomas; Practice
- MeSH: Brain; Central Nervous System; Chemoradiotherapy; Diagnosis; Drug Therapy; Glioblastoma; Humans; Korea; Radiotherapy
- From:Brain Tumor Research and Treatment 2019;7(1):1-9
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: There has been no practical guidelines for the management of patients with central nervous system (CNS) tumors in Korea for many years. Thus, the Korean Society for Neuro-Oncology (KSNO), a multidisciplinary academic society, started to prepare guidelines for CNS tumors from February 2018. METHODS: The Working Group was composed of 35 multidisciplinary medical experts in Korea. References were identified through searches of PubMed, MEDLINE, EMBASE, and Cochrane CENTRAL using specific and sensitive keywords as well as combinations of keywords. RESULTS: First, the maximal safe resection if feasible is recommended. After the diagnosis of a glioblastoma with neurosurgical intervention, patients aged ≤70 years with good performance should be treated by concurrent chemoradiotherapy with temozolomide followed by adjuvant temozolomide chemotherapy (Stupp's protocol) or standard brain radiotherapy alone. However, those with poor performance should be treated by hypofractionated brain radiotherapy (preferred)±concurrent or adjuvant temozolomide, temozolomide alone (Level III), or supportive treatment. Alternatively, patients aged >70 years with good performance should be treated by hypofractionated brain radiotherapy+concurrent and adjuvant temozolomide or Stupp's protocol or hypofractionated brain radiotherapy alone, while those with poor performance should be treated by hypofractionated brain radiotherapy alone or temozolomide chemotherapy if the patient has methylated MGMT gene promoter (Level III), or supportive treatment. CONCLUSION: The KSNO's guideline recommends that glioblastomas should be treated by maximal safe resection, if feasible, followed by radiotherapy and/or chemotherapy according to the individual comprehensive condition of the patient.
